100 results on '"Brunner, Andrew M."'
Search Results
2. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
3. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
4. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
5. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database
6. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
7. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
8. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines
9. SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes
10. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
11. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
12. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
13. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials
14. Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation
15. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
16. Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement
17. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
18. Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors
19. AML-430 A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis of the Economic Burden Among Elderly Patients With Acute Myeloid Leukemia (AML) Treated With Hypomethylating Agents (HMA)
20. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
21. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
22. Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study
23. Incident adverse events following therapy for acute promyelocytic leukemia
24. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement
25. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
26. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
27. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
28. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis
29. Chapter 59 - Pathobiology of Acute Myeloid Leukemia
30. Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation
31. Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
32. A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
33. Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
34. A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
35. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
36. Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival
37. Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
38. Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
39. Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
40. The highs and lows of venetoclax with hypomethylating agents for refractory AML
41. Contributors
42. Chapter 151 - Hematologic Manifestations of Solid Tumors
43. Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
44. Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials
45. Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia
46. Access and Treatment Equity across the Comprehensive Cancer Center Catchment Area: Targets for Disparities Remediation in Acute Leukemia Research Participation
47. Clustered incidence of adult acute promyelocytic leukemia
48. Chapter 155 - Hematologic Manifestations of Malignancy
49. Chapter 58 - Pathobiology of Acute Myeloid Leukemia
50. Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.